

VU Research Portal

89Zr-immuno-PET

Jauw, Y.W.S.

2019

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Jauw, Y. W. S. (2019). *89Zr-immuno-PET: Towards a clinical tool to guide antibody-based therapy in cancer*. [PhD-Thesis - Research and graduation internal, Vrije Universiteit Amsterdam].

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

CONTENTS

Chapter 1	General introduction	9
Part I	Feasibility of ^{89}Zr-immuno-PET	19
Chapter 2	Radiation dosimetry of ^{89}Zr -labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. <i>J Nucl Med.</i> 2009;50:1828-36	21
Chapter 3	Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. <i>Clin Can Res.</i> 2006;12:2133-40	43
Chapter 4	Immuno-positron emission tomography with Zirconium-89-labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials? <i>Front Pharmacol.</i> 2016;24;7:131	63
Part II	Validation of ^{89}Zr-immuno-PET	95
Chapter 5	Noise-induced variability of immuno-PET with Zirconium-89-labeled antibodies: an analysis based on count-reduced clinical images. <i>Mol Imaging Biol.</i> 2018;20:1025-1034	97
Chapter 6	Interobserver reproducibility of tumor uptake quantification with ^{89}Zr -immuno-PET: a multicenter analysis. <i>Eur J Nucl Med Mol Imaging.</i> 2019; 2019;46:1840-1849	121

Chapter 7	Performance of ^{89}Zr -labeled-rituximab-PET as an imaging biomarker to assess CD20 targeting: a pilot study in patients with relapsed/refractory diffuse large B cell lymphoma. <i>PLoS ONE</i> . 2017;12:e0169828.	141
Chapter 8	Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody. <i>EJNMMI Res</i> . 2018; 8:6.	157
Chapter 9	^{89}Zr -immuno-PET: towards a non-invasive clinical tool to measure target engagement of therapeutic antibodies in-vivo. <i>J Nucl Med</i> . 2019; Epub ahead of print	175
Chapter 10	Summary and discussion	195
Addendum		211
	Nederlandse samenvatting	213
	Acknowledgements / Dankwoord	222
	Curriculum vitae	224
	List of publications	225
	List of abbreviations	230